Two Orphan Drug Designations Granted for Reviroc in NHL

Publication
Article
OncologyONCOLOGY Vol 22 No 14
Volume 22
Issue 14

The biopharmaceutical company Kiadis Pharma recently announced that the US Food and Drug Administration (FDA) has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma (NHL)-one for diffuse large B-cell lymphoma and the other for the treatment of follicular lymphoma.

The biopharmaceutical company Kiadis Pharma recently announced that the US Food and Drug Administration (FDA) has granted its product Reviroc orphan drug designations for the treatment of two types of non-Hodgkin lymphoma (NHL)-one for diffuse large B-cell lymphoma and the other for the treatment of follicular lymphoma. Reviroc is under development for the elimination of cancer cells from an autologous graft in bone marrow transplantations for end-stage blood cancer patients.

Articles in this issue
The Absent-Minded Professor: An Unusual Complication of Melanoma
The Absent-Minded Professor: An Unusual Complication of Melanoma
Inflammatory Breast Cancer: A Complex Disease
Defining the IBC Phenotype
Acupuncture
Acupuncture
Two Orphan Drug Designations Granted for Reviroc in NHL
NDA Submitted for Trabectedin to Treat Relapsed Ovarian Cancer
FDA Considers Update for Tanning Bed Labels
FDA Approves New Imaging System to Enhance Cervical Cancer Detection
Fostamatinib Is Well-Tolerated and Has Significant Clinical Activity in Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia
Dexamethasone in Induction Can Eliminate One-Third of All Relapses in Childhood Acute Lymphoblastic Leukemia
Novel Antifolate Pralatrexate Shows Promise in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma
Alemtuzumab May Lead to Longer Overall Survival in CLL Patients With Poor Prognostic Factors
21st Century Challenge of Ovarian Cancer in the Elderly
21st Century Challenge of Ovarian Cancer in the Elderly
Molecular Determinants of the Inflammatory Breast Cancer Phenotype
Recent Videos
Related Content
Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

Teclistamab Real-World Data and Trial Results Show Promise in R/R Multiple Myeloma

ONCOLOGY Staff
August 19th 2025
Article

Experts discussed teclistamab's efficacy in multiple myeloma, highlighting real-world data and treatment protocols.

Stem Cell Transplant Approaches for Patients With Blood Cancers

Stem Cell Transplant Approaches for Patients With Blood Cancers

David T. Scadden, MD
March 13th 2019
Podcast

Dr. Scadden discusses which blood cancer patients are eligible for stem cell transplantation, as well as the latest advances in the field.

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

Analyzing Long-Term Follow-Up Results From MonumenTAL-1 in Multiple Myeloma

ONCOLOGY Staff
August 17th 2025
Article

Experts discussed talquetamab's unique mechanism and favorable patient outcomes in relapsed/refractory multiple myeloma.

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Current Treatment of Esophageal Cancer and Promising Clinical Trials Underway

Geoffrey Y. Ku, MD
March 13th 2019
Podcast

Dr. Ku discusses considerations in the treatment of esophageal cancer, current treatments, and the emerging role of immunotherapy.

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD
August 15th 2025
Article

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Unveiling the Potential of Zenocutuzumab: A Breakthrough in NSCLC and Pancreatic Adenocarcinoma Treatment

Sanan Rasheed, MBBS;Umer Farooq, MBBS;Aiman Waheed, MBBS;Musharaf Khalid Bhutta, MBBS;Adnan Bhat, MD;Hamza Nazir, MBBS;Muhammad Hamza Gul, MBBS, MD;Ayesha Aman, MBBS;Zainab Ibrahim, MBBS;Abdul Baseer Wardak, MBBS
August 14th 2025
Article

Zenocutuzumab offers a targeted treatment for NRG1+ lung and pancreatic cancers, demonstrating promising efficacy and manageable adverse effects.